Form 8-K Viking Therapeutics, For: Mar 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
March 26, 2024 11:20 AM EDTBTIG analyst Justin Zelin raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $125.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Viking is up +~25% (vs +0.75% XBI) this morning following presentation of impressive first in human data for oral VK2735, demonstrating 3.3% pbo adj weight loss in the highest dose cohort (40mg QD, n=7) at 28-days with an... More
